NASDAQ:JUNS Jupiter Neurosciences (JUNS) Stock Price, News & Analysis $3.01 -0.40 (-11.73%) Closing price 04:00 PM EasternExtended Trading$3.13 +0.12 (+3.99%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Jupiter Neurosciences Stock (NASDAQ:JUNS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jupiter Neurosciences alerts:Sign Up Key Stats Today's Range$3.00▼$3.4550-Day Range$3.01▼$14.7052-Week Range$2.88▼$137.96Volume57,792 shsAverage Volume2.73 million shsMarket Capitalization$2.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida. Read More Jupiter Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreJUNS MarketRank™: Jupiter Neurosciences scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingJupiter Neurosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageJupiter Neurosciences has only been the subject of 1 research reports in the past 90 days.Read more about Jupiter Neurosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Jupiter Neurosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jupiter Neurosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Jupiter Neurosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.14% of the float of Jupiter Neurosciences has been sold short.Short Interest Ratio / Days to CoverJupiter Neurosciences has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jupiter Neurosciences has recently increased by 91.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJupiter Neurosciences does not currently pay a dividend.Dividend GrowthJupiter Neurosciences does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.44 News SentimentJupiter Neurosciences has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Jupiter Neurosciences this week, compared to 2 articles on an average week.Search Interest3 people have searched for JUNS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jupiter Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders38.60% of the stock of Jupiter Neurosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsJupiter Neurosciences has minimal institutional ownership at this time.Read more about Jupiter Neurosciences' insider trading history. Receive JUNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jupiter Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JUNS Stock News HeadlinesJupiter Neurosciences Shares Plunge After Nasdaq Delisting NoticeAugust 31, 2026 | rttnews.comJupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct OfferingAugust 22, 2026 | finanznachrichten.deYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 15 at 1:00 AM | Profits Run (Ad)Jupiter Neurosciences stock surges Friday: What's driving the action?August 21, 2026 | msn.comJupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct OfferingAugust 21, 2026 | globenewswire.comJupiter Neurosciences, Inc. Announces 1-for-75 Reverse Stock Split Effective August 6, 2026August 5, 2026 | quiverquant.comQJupiter Neurosciences, Inc. Announces Reverse Stock SplitAugust 5, 2026 | globenewswire.comPsychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison SilvaJuly 22, 2026 | finance.yahoo.comSee More Headlines JUNS Stock Analysis - Frequently Asked Questions How have JUNS shares performed this year? Jupiter Neurosciences' stock was trading at $76.50 at the beginning of 2026. Since then, JUNS shares have decreased by 96.1% and is now trading at $3.01. How were Jupiter Neurosciences' earnings last quarter? Jupiter Neurosciences, Inc. (NASDAQ:JUNS) announced its quarterly earnings data on Friday, August, 14th. The company reported ($5.06) earnings per share for the quarter, missing analysts' consensus estimates of ($3.75) by $1.31. The company earned $0.02 million during the quarter, compared to the consensus estimate of $0.40 million. When did Jupiter Neurosciences' stock split? Jupiter Neurosciences's stock reverse split on the morning of Friday, August 7th 2026.A 1-75 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 6th 2026. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Jupiter Neurosciences IPO? Jupiter Neurosciences (JUNS) raised $11 million in an initial public offering (IPO) on Tuesday, December 3rd 2024. The company issued 2,800,000 shares at $4.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO. How do I buy shares of Jupiter Neurosciences? Shares of JUNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today9/15/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, JUNS's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JUNS CIK1679628 Webjupiterneurosciences.com Phone561 406 6154FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($19.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.65 million Net MarginsN/A Pretax Margin-14,152.31% Return on Equity-1,314.62% Return on Assets-246.66% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.62 Sales & Book Value Annual Sales$20 thousand Price / Sales136.96 Cash FlowN/A Price / Cash FlowN/A Book Value($4.00) per share Price / Book-0.75Miscellaneous Outstanding Shares910,000Free Float561,000Market Cap$2.74 million OptionableNot Optionable Beta1.81 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:JUNS) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
